On September 16, 2024, Javier Rodriguez, CEO of DaVita Inc (DVA, Financial), executed a sale of 59,881 shares of the company at a price of $164.69 per share. This transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 837,835 shares of DaVita Inc.
DaVita Inc specializes in kidney care and dialysis services, operating numerous outpatient dialysis centers across the United States. The company is known for providing a range of dialysis services for patients diagnosed with chronic kidney failure.
Over the past year, the insider has sold a total of 175,000 shares and has not made any purchases of the company's stock. This recent transaction is part of a broader trend observed over the past year, where DaVita Inc has seen 10 insider sells and no insider buys.
As of the date of the transaction, DaVita Inc shares were trading at $164.69, giving the company a market cap of approximately $13.78 billion. The price-earnings ratio of the stock stands at 17.49, which is below both the industry median of 23.58 and the company’s historical median.
According to the GF Value, an intrinsic value estimate developed by GuruFocus, DaVita Inc is currently significantly overvalued with a price-to-GF-Value ratio of 1.41. The GF Value of $116.69 is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates from analysts.
This insider sale might interest investors tracking insider behaviors as an indicator of the company’s future performance and valuation alignment.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
